Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.47 |
| ▸ | CHRNG | P07510 | 4/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.47 |
| ▸ | CHRND | Q07001 | 4/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277213 | 1.00 | C3AR1 (0.53) | C3AR1NPY1RCHRNA1CHRNGCHRNB1 | |
| Phenylalanine Amide SCHEMBL7535742 | 0.91 | CHRNA1 (0.46) | C3AR1NPY1RCHRNA1CHRNGCHRNB1 | |
| SCHEMBL30423373 | 0.85 | NPY4R (0.47) | NPY1RCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL8423661 | 0.85 | CTSG (0.54) | C3AR1NPY1RITGB3ITGA2B | |
| SCHEMBL7786354 | 0.85 | FOLH1 (0.49) | C3AR1NPY1RITGB3SHMT1 | |
| SCHEMBL7786368 | 0.85 | FOLH1 (0.49) | C3AR1NPY1RITGB3SHMT1 | |
| SCHEMBL7535795 | 0.85 | NPY4R (0.59) | NPY1RCHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL6801489 | 0.84 | C3AR1 (0.61) | C3AR1SHMT1HPGD | |
| SCHEMBL7653534 | 0.83 | GPR34 (0.57) | C3AR1 | |
| SCHEMBL4650743 | 0.83 | NPY1R (0.61) | NPY1RCHRNA1CHRNGCHRNB1CHRND |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629319-B2 | Heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-08 | — | — | US | disclosed |
| US-7618945-B2 | Heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-11-17 | — | — | US | disclosed |
| US-20060009396-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | US | disclosed |
| EP-1578786-A2 | HETEROARYL PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004060913-A2 | HETEROARYL PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-22 | — | — | WO | disclosed |
| US-20040138141-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009396-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | C3AR1 104/4885NPY1R 292/4885CHRNA1 1540/4885 |
| US-20040138141-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | C3AR1 104/4885NPY1R 292/4885CHRNA1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.